With the United Kingdom recently legislating a permanent ban on cigarette sales for anyone born after 2008, the insurance world is facing a structural shift that could redefine risk for the next century. This “smoke-free generation” policy isn’t just a headline for public health; it is a fundamental recalibration of the actuarial tables that underpin life and health insurance. Simon Glairy, a distinguished expert in risk management and Insurtech, joins us to discuss how this radical departure from traditional social trends creates a hard policy input for long-term modeling. We explore the transformation of risk pools, the divergence of international mortality data, and the potential for these legislative ripples to cross the Atlantic and reshape the American insurance landscape.
Legislation that permanently bans cigarette sales to younger generations creates a structural shift in long-term risk. How would a chief actuary model the impact on 30-year term life policies, and what specific metrics would they prioritize to adjust for a population with near-zero smoking prevalence?
A chief actuary would approach this by shifting from “social trend estimates” to “hard policy inputs,” which are far more valuable for long-run pricing. For a 30-year term policy, we would prioritize mortality tables and loss ratios specifically for the cohort born on or after January 1, 2009. We aren’t just looking at a slight decline in users; we are modeling a floor where the smoking prevalence rate drops toward zero, which is a massive historical anomaly. The primary metrics would include the frequency of critical illness payouts and long-term mortality rates, as smoking currently causes roughly one in five deaths in the United States. By removing this variable, we can project a population that lives longer and draws significantly less on life insurance resources in their middle decades.
With smoking-related illnesses costing the U.S. hundreds of billions annually, how should health insurers restructure their long-tail product pricing? Can you walk through the step-by-step process of evaluating how a smoke-free cohort alters catastrophic claim projections for conditions like heart disease and COPD?
The restructuring begins with acknowledging that smoking cost the U.S. over $600 billion in 2018 alone, with $240 billion of that being direct healthcare spending. To evaluate a smoke-free cohort, we first isolate the data for chronic obstructive pulmonary disease (COPD), lung cancer, and stroke, which are the most expensive catastrophic claims. Next, we apply a “generational filter” to our models, recognizing that while immediate costs won’t change, the claims trajectory for the younger cohort bends downward over a 10 to 30-year horizon. We then calculate the compounding effect of zero-uptake, which suggests a future where hospital stays are shorter and the frequency of high-cost chronic treatments is drastically reduced. Finally, we adjust the premiums for these long-tail products to reflect a genuinely lower-risk population, allowing for healthier margins or more competitive pricing.
When a national policy targeting smoking cessation is repealed or reversed due to shifting political priorities, how does that volatility affect the reliability of reinsurance pricing? What differences do you see in the institutional stability of public health initiatives between centralized versus fragmented regulatory environments?
The volatility seen in New Zealand, where a similar ban was enacted in 2022 and repealed in 2024 to fund tax cuts, serves as a cautionary tale for reinsurers who rely on stability. When a policy is reversed, the “hard input” reverts to a “soft trend,” forcing firms like Swiss Re or Munich Re to re-introduce higher risk premiums to account for political uncertainty. In a centralized environment like the UK, the National Health Service (NHS) provides a powerful institutional anchor that makes the policy more durable and the data more reliable. Conversely, fragmented environments like the U.S. introduce “regulatory noise,” where state-level shifts make it difficult to price national reinsurance treaties with any degree of certainty. This difference in institutional stability directly dictates whether an actuary can confidently bake legislative success into a 30-year pricing model.
In light of the political hurdles for federal tobacco bans in the U.S., how might state-level rolling age bans affect regional health plans? What specific data or early indicators would you look for to prove that these policies are successfully bending the claims trajectory downward?
State-level bans in places like California or Massachusetts would create “laboratory markets” that regional health plans must navigate with precision. To prove these policies are working, I would look for a divergence in youth respiratory treatment frequency and early-onset asthma claims compared to states without such bans. While the full impact on lung cancer takes decades, early indicators such as a reduction in tobacco-related primary care visits among the affected age group would be a vital sign. If regional data starts to show that these younger cohorts are avoiding the traditional “uptake” phase, insurers can begin to lower the expected loss ratios for those specific regional pools. This provides a measurable informational advantage that can be used to justify lower premiums for certain zip codes or states.
Since the insurance industry has a clear financial interest in lower smoking rates, should carriers become more aggressive proponents of public health mandates? How would such advocacy impact their relationship with corporate clients, and what are the potential trade-offs of this direct involvement?
The insurance industry has a quantifiable financial stake in this fight that is arguably larger than any other sector, and there is a strong case for carriers to move beyond passive support. By becoming aggressive proponents, carriers could leverage the UK precedent as a concrete economic model to show corporate clients how these mandates protect their workforce productivity—noting that smoking cost $372 billion in lost productivity in 2018. However, the trade-off involves navigating the American tradition of individual liberty, which might cause friction with clients who view such advocacy as “public health paternalism.” There is also the risk of political backlash in tobacco-heavy states like North Carolina or Kentucky, where the industry’s lobbying power remains a formidable counterweight to insurance-led health mandates.
The Affordable Care Act allows insurers to charge smokers significantly higher premiums, though enforcement remains inconsistent. If data begins to show a massive decline in smoking-related deaths elsewhere, how would this change the case for more aggressive underwriting and wellness program investment in the American market?
If the UK data shows a measurable improvement in mortality over the next decade, it will give U.S. carriers the empirical ammunition they need to enforce the ACA’s 50 percent premium surcharge more strictly. Currently, enforcement is often soft, but clear evidence of a “smoke-free” health dividend would shift the underwriting philosophy from reactive to proactive. We would likely see a surge in wellness program investments, with carriers using the British results to prove to stakeholders that the ROI on smoking cessation is guaranteed by the mathematics of the risk pool. It transforms smoking from a lifestyle choice into a primary underwriting tier, making it as fundamental to the policy structure as age or pre-existing conditions.
What is your forecast for the future of the smoke-free generation’s impact on global insurance markets?
I forecast that over the next 15 years, we will see a significant divergence in international mortality data, where the UK begins to outperform the U.S. and other nations that rely on incremental tobacco control. This divergence will force global reinsurers to create a two-tiered pricing system: one for “protected” populations with structural smoking bans and another for “legacy” risk environments where smoking remains a social variable. As the British cohort ages, the data will provide a “gold standard” for what a low-cost, high-longevity population looks like, eventually pressuring other developed economies to adopt similar legislative floors to keep their own insurance markets competitive. We are moving toward a future where “non-smoker” is no longer a self-reported status, but a legally guaranteed actuarial certainty for entire generations.
